Comparative Pharmacology
Head-to-head clinical analysis: AZDONE versus PHENAZINE 35.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AZDONE versus PHENAZINE 35.
AZDONE vs PHENAZINE-35
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
AZDONE is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the central nervous system by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
PHENAZINE-35 is a synthetic phenazine derivative that inhibits bacterial DNA synthesis by intercalating into DNA and disrupting topoisomerase IV activity, leading to cell death.
10 mg orally once daily
25 mg orally three times daily, titrated to a maximum of 100 mg three times daily.
None Documented
None Documented
Terminal elimination half-life: 18 hours; clinically relevant for once-daily dosing
Terminal half-life: 12-18 hours (mean 15 h). Clinically, steady-state achieved in ~3 days, allows once-daily dosing.
Renal: 60% unchanged; fecal: 30% as metabolites; biliary: 10% as conjugates
Renal: ~70% (30% unchanged, 40% as metabolites); Biliary/Fecal: ~30%
Category C
Category C
Urinary Analgesic
Urinary Analgesic